These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29733407)

  • 1. Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?
    Mazzaferro S; Cianciolo G; De Pascalis A; Guglielmo C; Urena Torres PA; Bover J; Tartaglione L; Pasquali M; La Manna G
    Nephrol Dial Transplant; 2018 Dec; 33(12):2092-2100. PubMed ID: 29733407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era.
    Mazzaferro S; Bagordo D; De Martini N; Pasquali M; Rotondi S; Tartaglione L; Stenvinkel P;
    Calcif Tissue Int; 2021 Apr; 108(4):452-460. PubMed ID: 33388898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management.
    Lewis R
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Osteodystrophy-Time for Common Nomenclature.
    Ott SM
    Curr Osteoporos Rep; 2017 Jun; 15(3):187-193. PubMed ID: 28466454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis management in patient with renal function impairment.
    Lima GA; Paranhos Neto Fde P; Pereira GR; Gomes CP; Farias ML
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):530-9. PubMed ID: 25166044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.
    Lundquist AL; Nigwekar SU
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adynamic bone disease: from bone to vessels in chronic kidney disease.
    Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ
    Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update].
    Okuno S
    Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow immunoscintigraphy (BMIS): a new and important tool for the assessment of marrow fibrosis in renal osteodystrophy?
    Kim CD; Kim SH; Kim YL; Cho DK; Lee JT
    Adv Perit Dial; 1998; 14():183-7. PubMed ID: 10649720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM; Schiavi SC
    Semin Dial; 2015; 28(6):578-86. PubMed ID: 26288182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone kidney interactions.
    Nickolas TL; Jamal SA
    Rev Endocr Metab Disord; 2015 Jun; 16(2):157-63. PubMed ID: 26156535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis and adynamic bone in chronic kidney disease.
    Cannata-Andía JB; Rodriguez García M; Gómez Alonso C
    J Nephrol; 2013; 26(1):73-80. PubMed ID: 23023723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. News on biomarkers in CKD-MBD.
    Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
    Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production.
    Liao HW; Huang TH; Chang YH; Liou HH; Chou YH; Sue YM; Hung PH; Chang YT; Ho PC; Tsai KJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.
    Malluche HH; Monier-Faugere MC; Blomquist G; Davenport DL
    Osteoporos Int; 2018 Jan; 29(1):125-134. PubMed ID: 28993865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal osteodystrophy, phosphate homeostasis, and vascular calcification.
    Hruska KA; Saab G; Mathew S; Lund R
    Semin Dial; 2007; 20(4):309-15. PubMed ID: 17635820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.